Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06075667
PHASE3

A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Sponsor: Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity or overweight with at least one weight-related comorbidity. The study will last approximately 90 weeks and may include up to 25 visits. Participants who have completed the primary 72-week GPHP study and have been off treatment for no more than 12 weeks (including the 4-week safety follow-up period), will have the opportunity to receive an additional 156 weeks of treatment with tirzepatide as well as continuing the lifestyle intervention.

Official title: Efficacy, Safety, and Pharmacokinetics of Tirzepatide Once Weekly Versus Placebo in Adolescent Participants Who Have Obesity, or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind Trial (SURMOUNT-ADOLESCENTS)

Key Details

Gender

All

Age Range

12 Years - 17 Years

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2023-10-16

Completion Date

2029-07

Last Updated

2025-06-25

Healthy Volunteers

No

Interventions

DRUG

Tirzepatide

Administered SC

DRUG

Placebo

Administered SC

Locations (33)

CenExel iResearch, LLC

Decatur, Georgia, United States

Solaris Clinical Research

Meridian, Idaho, United States

Cotton O'Neil Diabetes & Endocrinology

Topeka, Kansas, United States

Pennington Biomedical Research Center

Baton Rouge, Louisiana, United States

Barry J. Reiner, MD, LLC

Baltimore, Maryland, United States

M Health Fairview - Delaware Clinical Research Unit (DCRU)

Minneapolis, Minnesota, United States

Washington University School of Medicine

St Louis, Missouri, United States

Aventiv Research Inc

Columbus, Ohio, United States

PriMED Clinical Research

Dayton, Ohio, United States

Vanderbilt Health One Hundred Oaks

Nashville, Tennessee, United States

Alberta Diabetes Institute

Edmonton, Alberta, Canada

The Wharton Medical Clinic Clinical Trials Inc

Hamilton, Ontario, Canada

The Hospital for Sick Children

Toronto, Ontario, Canada

CIUSSS- saguenay-Lac-Saint-Jean

Chicoutimi, Quebec, Canada

ReFit Clinic

Olomouc, Olomoucký kraj, Czechia

Nemocnice AGEL Ostrava - Vitkovice a.s.

Ostrava, Ostrava Město, Czechia

Fakultni nemocnice v Motole

Prague, Praha 5, Czechia

Nemocnice Jihlava

Jihlava, Czechia

Fakultni nemocnice Kralovske Vinohrady

Prague, Czechia

Yitzhak Shamir Medical Center

Beer Yaacov, Central District, Israel

Schneider Children's Medical Center

Petah Tikva, Central District, Israel

Sheba Medical Center

Ramat Gan, Central District, Israel

Shaare Zedek Medical Center

Jerusalem, Jerusalem, Israel

Emek Medical Center

Afula, Northern District, Israel

Rambam Health Care Campus

Haifa, Northern District, Israel

Soroka Medical Center

Beersheba, Southern District, Israel

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola

Bologna, Emilia-Romagna, Italy

Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento

Verona, Veneto, Italy

Azienda Ospedaliera Universitaria Di Messina G. Martino

Messina, Italy

Azienda Ospedaliero Universitaria Maggiore della Carità

Novara, Italy

Instytut Diabetologii

Warsaw, Masovian Voivodeship, Poland

Samodzielny Publiczny Szpital Kliniczny nr 1 SUM

Zabrze, Silesian Voivodeship, Poland

Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi, Uniwersyteckie Centrum Pediatrii im. M. Konop -T

Lodz, Łódź Voivodeship, Poland